COMMUNIQUÉS West-GlobeNewswire

LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.
02/12/2025
EXOUSIA AI SECURES HIGH-VALUE ORPHAN DRUG DESIGNATION ORLANDO, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the “Company” or “Exo Bio”), operating as a leading U.S. [...]
LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.
02/12/2025
EXOUSIA AI SECURES HIGH-VALUE ORPHAN DRUG DESIGNATION ORLANDO, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the “Company” or “Exo Bio”), operating as a leading U.S. [...]
Health-ISAC® Announces results of 2026 Board of Directors Election
02/12/2025
ORLANDO, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Health Information Sharing and Analysis Center (Health-ISAC), the non-profit world-class, industry-led sharing organization that provides the global health sector with a [...]
GUERBET : Adjustment of 2025 financial targets.
02/12/2025
Adjustment of 2025 financial targets Villepinte, 2 December 2025, 5.45 p.m. : Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing a downward revision to [...]
GUERBET : Ajustement des objectifs financiers 2025.
02/12/2025
Ajustement des objectifs financiers 2025 Villepinte, le 02 décembre 2025, 17h45 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, annonce une révision à [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 48 - 2025
02/12/2025
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 24 Novembre au 28 Novembre 2025 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 48 - 2025
02/12/2025
Aggregated presentation by day and by market Statement of transactions in own shares from November 24th to November 28th 2025 Name of the issue Identity code of the issuer (Legal Entity Identifier) Day of the [...]
Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
02/12/2025
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics , a biopharmaceutical company specializing in developing transformative treatments for rare diseases, announced the initiation of a pivotal Phase III [...]
Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
02/12/2025
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics , a biopharmaceutical company specializing in developing transformative treatments for rare diseases, announced the initiation of a pivotal Phase III [...]
Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following Continued November Purchases
02/12/2025
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that Chief Executive Officer [...]
AMPS Achieves HITRUST e1 Certification, Solidifying Commitment to Data Security in Healthcare
02/12/2025
PHOENIX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- AMPS , a healthcare technology solutions company serving self-insured employer groups, payors, healthcare brokers and consultants, and third-party administrators, announced [...]
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
02/12/2025
— New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a P hase 3 Registration Trial — TEL AVIV, Israel, Dec. 02, [...]
Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
02/12/2025
DURHAM, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos [...]
Oncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs
02/12/2025
AGOURA HILLS, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano , a clinical-stage nanomedicine company, today announced new data demonstrating that [...]
Genvor and Tuskegee University Announce Teaming Agreement to Advance Peptide Research and Sustainable Crop Protection Technologies
02/12/2025
Woodland, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTC: GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, today announced it has entered into a formal teaming agreement with [...]
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer
02/12/2025
Positive feedback reinforces Silexion’s trajectory toward its planned Phase 2/3 trial initiation in Q2 2026 Company plans to complete regulatory submissions to the Israeli Ministry of Health by the end of Q4 2025 and in [...]
Amneal to Participate in Upcoming Investor Conferences
02/12/2025
BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financial Officer, will [...]
DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its Portfolio
02/12/2025
DNA-based Colorectal Cancer Screening as a Home Test BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), molecular genetics [...]
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
02/12/2025
SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced [...]

Pages